Did you like this article? Please share it.
InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by integrating bioanalytical and computational pharmacology in collaborative projects with biotech and pharma companies. This month, the start-up closed another financing round and raised CHF 3 Mio for the commercialization of its platform.
InterAx Biotech AG pioneers computational pharmacology for drug discovery. It applies mathematical models and simulations to in-house derived experimental data in order to address the complexity of drug-induced cellular signaling mechanisms. The company's goal is to close the gap between laboratory experiments and in vivo studies by streamlining the critical processes of drug candidate design and selection, thereby significantly reducing the risks, costs, and duration of drug discovery and development of new drugs.
The company has now closed a financing round of three million Swiss francs. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the company's technology platform. In addition, InterAx appointed Dr. Bettina Ernst founder and CEO of Preclin Biosystems as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.